Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $117.08 USD
Change Today +1.63 / 1.41%
Volume 11.2M
GILD On Other Exchanges
As of 4:15 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

gilead sciences inc (GILD) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/24/15 - $123.37
52 Week Low
06/30/14 - $82.63
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GILEAD SCIENCES INC (GILD)

gilead sciences inc (GILD) Details

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company’s products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with Bristol-Myers Squibb Company, Janssen R&D Ireland, and Japan Tobacco Inc. to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.

7,000 Employees
Last Reported Date: 02/25/15
Founded in 1987

gilead sciences inc (GILD) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.6M
President and Chief Operating Officer
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $797.6K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $920.6K
Executive Vice President of Corporate & Medic...
Total Annual Compensation: $814.3K
Compensation as of Fiscal Year 2014.

gilead sciences inc (GILD) Key Developments

The Medicines Patent Pool and Gilead Sciences Expand Licence to Allow Generic Manufacture of Medicines in South Africa

The Medicines Patent Pool (MPP) announced an expansion of its current licensing agreement with Gilead Sciences for generic manufacture of tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF) and other Gilead medicines. The amendment enhances MPP's current licence by allowing South African manufacturers to join Indian and Chinese companies in developing generics for low- and middle-income countries. The revision builds on MPP's long-term collaboration with Gilead Sciences for the production of TDF, emtricitabine (FTC), cobicistat (COBI), and elvitegravir (EVG), as well as a single tablet regimen of all four ARVs. In 2014, Gilead Sciences and the MPP amended the agreement to include the investigational medicine TAF and to expand the manufacturing of the licensed medicines TAF, TDF, FTC and COBI to Chinese companies. With a licence for TAF, an investigational antiretroviral currently in US regulatory review, the MPP seeks to encourage the rapid introduction of new therapies in developing countries in line with their rollout in the US and Europe. Eight MPP Indian and Chinese manufacturers are currently developing TAF, and thus the medicine could be registered in low- and middle-income countries shortly after it receives FDA approval. MPP announced that new generic partners, HEC Pharm and Huahai Pharmaceutical, based in China, have signed sub-licensing agreements to develop TAF as well. Under the amended licence, Chinese and South African companies can now also manufacture EVG. As well, patents on the combination of TDF/FTC with efavirenz (EFV), the WHO-recommended first-line regimen for adults, have been added to the licence. MPP's first cooperative efforts with Gilead Sciences have demonstrated significant impact for communities living with HIV. The price of TDF has dropped 41%-90% since the MPP signed its first licence with the company. MPP's generic partners have distributed approximately two billion TDF treatments in the same time period.

Receptos Reportedly Rejects Takeover Bids

Receptos, Inc. (NasdaqGS:RCPT) has rejected takeover offers from AstraZeneca PLC (LSE:AZN), Gilead Sciences Inc. (NasdaqGS:GILD) and Teva Pharmaceutical Industries Limited (NYSE:TEVA), according to sources. AstraZeneca offered $200 per share while Gilead and Teva offered $280 per share, sources reported. Receptos reportedly rejected offers claiming they undervalued it.

Gilead Sciences Inc. Announces Results from the Phase 3 Clinical Study 119 of an Investigational Use of Zydelig

Gilead Sciences Inc. announced results from the Phase 3 clinical Study 119 of an investigational use of Zydelig® (idelalisib) in combination with ofatumumab in previously-treated patients with chronic lymphocytic leukemia (CLL). In Study 119, there was a 73% reduction in the risk of disease progression or death in patients receiving Zydelig in combination with ofatumumab compared to ofatumumab alone (hazard ratio (HR) = 0.27; 95% CI: 0.19, 0.39.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GILD:US $117.08 USD +1.63

GILD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $67.19 USD +0.01
Amgen Inc $153.52 USD +1.92
GlaxoSmithKline PLC 1,323 GBp -23.00
Merck & Co Inc $56.93 USD -0.36
Sanofi €88.24 EUR -1.29
View Industry Companies

Industry Analysis


Industry Average

Valuation GILD Industry Range
Price/Earnings 13.2x
Price/Sales 6.3x
Price/Book 9.9x
Price/Cash Flow 11.9x
TEV/Sales 5.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GILEAD SCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at